Analysts Set Harrow, Inc. (NASDAQ:HROW) Price Target at $69.86

Harrow, Inc. (NASDAQ:HROW) has been given an average recommendation of “Moderate Buy” by the eleven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $69.8571.

A number of equities analysts have weighed in on the stock. BTIG Research reiterated a “buy” rating and issued a $63.00 price target on shares of Harrow in a research report on Wednesday, March 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Nomura lowered shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. William Blair restated an “outperform” rating on shares of Harrow in a research report on Tuesday, March 3rd. Finally, Cantor Fitzgerald lowered their price objective on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th.

Harrow Stock Performance

Shares of HROW opened at $35.93 on Wednesday. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The business has a 50-day simple moving average of $41.44 and a two-hundred day simple moving average of $42.89. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -211.34 and a beta of 0.31. Harrow has a 52 week low of $21.12 and a 52 week high of $54.85.

Hedge Funds Weigh In On Harrow

Several large investors have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Harrow by 102.5% during the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after buying an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after buying an additional 790 shares during the last quarter. Strs Ohio bought a new stake in shares of Harrow during the first quarter valued at approximately $149,000. Legal & General Group Plc raised its position in shares of Harrow by 12.4% during the second quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock valued at $939,000 after buying an additional 3,384 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Harrow by 9.3% during the second quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock valued at $1,434,000 after buying an additional 3,994 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.